Analysts expect that Akorn, Inc. (NASDAQ:AKRX) will announce $0.11 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Akorn’s earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.15. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Akorn will report full year earnings of $0.51 per share for the current financial year, with EPS estimates ranging from $0.49 to $0.52. For the next financial year, analysts anticipate that the company will post earnings of $0.45 per share, with EPS estimates ranging from $0.29 to $0.60. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Akorn.

Akorn (NASDAQ:AKRX) last issued its earnings results on Wednesday, August 1st. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.14). Akorn had a negative return on equity of 12.84% and a negative net margin of 24.21%. The company had revenue of $190.94 million during the quarter, compared to analysts’ expectations of $187.40 million.

AKRX has been the subject of several analyst reports. BidaskClub downgraded Akorn from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Zacks Investment Research raised Akorn from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, August 27th. Deutsche Bank reissued a “buy” rating on shares of Akorn in a report on Thursday, August 23rd. Finally, Royal Bank of Canada increased their price target on Akorn from $25.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.50.

Shares of NASDAQ AKRX traded up $0.22 on Wednesday, hitting $13.06. The company had a trading volume of 1,861,800 shares, compared to its average volume of 2,459,526. Akorn has a 12-month low of $10.76 and a 12-month high of $33.63. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.94 and a quick ratio of 2.87. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of 8.08, a PEG ratio of 1.55 and a beta of 1.92.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Akorn by 30.6% in the second quarter. BlackRock Inc. now owns 10,731,745 shares of the company’s stock valued at $178,040,000 after purchasing an additional 2,515,409 shares during the last quarter. Marshall Wace LLP boosted its holdings in Akorn by 250.5% in the second quarter. Marshall Wace LLP now owns 2,069,385 shares of the company’s stock valued at $34,331,000 after purchasing an additional 1,478,959 shares during the last quarter. Paulson & CO. Inc. purchased a new position in Akorn in the second quarter valued at about $29,198,000. Natixis boosted its holdings in Akorn by 31.3% in the second quarter. Natixis now owns 1,500,471 shares of the company’s stock valued at $24,893,000 after purchasing an additional 357,981 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Akorn by 75.7% in the second quarter. Northern Trust Corp now owns 1,409,291 shares of the company’s stock valued at $23,379,000 after purchasing an additional 607,101 shares during the last quarter. 69.81% of the stock is owned by hedge funds and other institutional investors.

Akorn Company Profile

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

See Also: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Akorn (AKRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.